CyBio AG closed the previous year succesful
Jena, (German Stock Exchange: General Standard, ISIN-Number DE0005412308) finished 2005 with sales of 14.28 Mio. EUR, an increase of 14.3 percent over previous year. Growth of sales was remarkably strong in the US-market.
The operational result has been improved significantly by 3.1 Mio. EUR. The unaudited group result accumulated to a profit of about 1 Mio. EUR, whereby each half year was closed positive.
On an annual basis CyBio generated additional cash of 3.1 Mio. EUR, including the issuance of new share capital. Not included herein is the expected cash flow from an increase in accounts receivables from supplies and services over prior year. At year end the Group has liquid funds available of 7.4 Mio. EUR (prior year 4.3 Mio. EUR).
These results show impressively the predicted turnaround at CyBio.
A week ago CyBio AG signed a distribution agreement with STRATEC Biomedical Systems AG for the sale of STRATEC’s flexible pipetting platform under CyBio’s name. This device enlarges CyBio’s equipment basis and enables sales into further life science industry market segments.
CyBio AG will publish the audited financial statement of 2005 on 30th March, 2006.
Sales 2005 english (15.15 kb): www.cybio-ag.com/files.php4?dl_mg_id=438&file=dl_mg_1138646918.pdf
- Contact Information
- Press Office
- CyBio AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.